Recent analyst calls around Globus Medical (GMED) have sharpened the market’s focus on the stock, following positive preliminary fourth quarter revenue, commentary on margin expansion, and fresh coverage tied to Nevro, international growth, and enabling technologies.

The recent upgrade and new coverage come after a period where short term share price momentum has cooled, with a 30 day share price return showing a 4.78% decline. In contrast, the 3 year total shareholder return of 50.52% points to a stronger long term record.

If this move in a medical technology name has your attention, you might also want to scan the wider healthcare technology space through our screener of 25 healthcare AI stocks as another source of ideas.

So with Globus Medical trading at $89.00 against an average analyst target of about $107 and estimates of intrinsic value also above the current price, is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 16.4% Undervalued

With Globus Medical closing at $89.00 against a widely followed fair value estimate of $106.40, the current price sits below what this narrative models as intrinsic value. This puts the focus squarely on the earnings and cash flow assumptions behind that gap.

Continued innovation and adoption of robotics, navigation, and minimally invasive procedures including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and robust product pipeline position Globus to capitalize on healthcare digitization trends, driving higher ASPs, stronger market differentiation, and improved gross margins over time.

Read the complete narrative. Read the complete narrative.

Readers may be curious what kind of revenue trajectory and long run margin profile are built into that fair value, and how a higher future earnings multiple is being justified on top of it, all while factoring in the updated discount rate and refreshed long term growth inputs, not just the latest quarter.

Based on this widely followed narrative, Globus Medical is modeled at a fair value of $106.40, which sits above the current $89.00 share price. Result: Fair Value of $106.40 (UNDERVALUED)

However, that upside view collides with potential headwinds if Nevro and NuVasive integration drags on profitability, or if slower international growth keeps revenue below those modeled paths.

Next Steps

If the mixed views in this article leave you unsure, it is worth reviewing the numbers yourself and moving quickly to form your own stance, starting with 4 key rewards.

Looking for more investment ideas?

If you are serious about sharpening your watchlist, do not stop with one stock. Let the screener surface opportunities that match the way you already think about risk and reward.

• Target dependable income by checking out our list of 13 dividend fortresses that could help anchor the more volatile parts of your portfolio.
• Hunt for potential value by reviewing 56 high quality undervalued stocks, where quality fundamentals meet prices that screen as below estimated worth.
• Prioritize sleep at night by scanning 80 resilient stocks with low risk scores, focusing on companies that screen with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.